FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:2545-2559 June 12, 2008 Number 24 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Perspective by Krumholz, H. M. Editorial by Dluhy, R. G. Editorial by Cefalu, W. T. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Epidemiologic studies have shown a relationship between glycated hemoglobin levels and cardiovascular events in patients with type 2 diabetes. We investigated whether intensive therapy to target normal glycated hemoglobin levels would reduce cardiovascular events in patients with type 2 diabetes who had either established cardiovascular disease or additional cardiovascular risk factors.

Methods In this randomized study, 10,251 patients (mean age, 62.2 years) with a median glycated hemoglobin level of 8.1% were assigned to receive intensive therapy (targeting a glycated hemoglobin level below 6.0%) or standard therapy (targeting a level from 7.0 to 7.9%). Of these patients, 38% were women, and 35% had had a previous cardiovascular event. The primary outcome was a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes. The finding of higher mortality in the intensive-therapy group led to a discontinuation of intensive therapy after a mean of 3.5 years of follow-up.

Results At 1 year, stable median glycated hemoglobin levels of 6.4% and 7.5% were achieved in the intensive-therapy group and the standard-therapy group, respectively. During follow-up, the primary outcome occurred in 352 patients in the intensive-therapy group, as compared with 371 in the standard-therapy group (hazard ratio, 0.90; 95% confidence interval [CI], 0.78 to 1.04; P=0.16). At the same time, 257 patients in the intensive-therapy group died, as compared with 203 patients in the standard-therapy group (hazard ratio, 1.22; 95% CI, 1.01 to 1.46; P=0.04). Hypoglycemia requiring assistance and weight gain of more than 10 kg were more frequent in the intensive-therapy group (P<0.001).

Conclusions As compared with standard therapy, the use of intensive therapy to target normal glycated hemoglobin levels for 3.5 years increased mortality and did not significantly reduce major cardiovascular events. These findings identify a previously unrecognized harm of intensive glucose lowering in high-risk patients with type 2 diabetes. (ClinicalTrials.gov number, NCT00000620 [ClinicalTrials.gov] .)

Source Information

The members of the writing group (Hertzel C. Gerstein, M.D., M.Sc., McMaster University and Hamilton Health Sciences, Population Health Research Institute, Hamilton, ON, Canada; Michael E. Miller, Ph.D., Robert P. Byington, Ph.D., and David C. Goff, Jr., M.D., Ph.D., Wake Forest University School of Medicine, Winston-Salem, NC; J. Thomas Bigger, M.D., Columbia University College of Physicians and Surgeons, New York; John B. Buse, M.D., Ph.D., University of North Carolina School of Medicine, Chapel Hill; William C. Cushman, M.D., Memphis Veterans Affairs Medical Center, Memphis, TN; Saul Genuth, M.D., and Faramarz Ismail-Beigi, M.D., Ph.D., Case Western Reserve University, Cleveland; Richard H. Grimm, Jr., M.D., Ph.D., Berman Center for Outcomes and Clinical Research, Minneapolis; Jeffrey L. Probstfield, M.D., University of Washington, Seattle; Denise G. Simons-Morton, M.D., Ph.D., National Heart, Lung, and Blood Institute, Bethesda, MD; and William T. Friedewald, M.D., Columbia University Mailman School of Public Health, New York) assume responsibility for the overall content and integrity of this article.

This article (10.1056/NEJMoa0802743) was published at www.nejm.org on June 6, 2008.

Address reprint requests to Dr. Byington at the Division of Public Health Sciences, Wake Forest University School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157, or at bbyingto{at}wfubmc.edu.

Full Text of this Article

Related Letters:

Intensive Glucose Control in Type 2 Diabetes
Jenny-Avital E. R., Luan F. L., Nguyen K., Tobey T. A., Parashar A., Byington R. P., Gerstein H. C., Friedewald W. T., Patel A., MacMahon S., Chalmers J.
Extract | Full Text | PDF  
N Engl J Med 2008; 359:1519-1521, Oct 2, 2008. Correspondence

This article has been cited by other articles:

• Lund, S. S, Tarnow, L., Frandsen, M., Nielsen, B. B, Hansen, B. V, Pedersen, O., Parving, H.-H., Vaag, A. A (2009). Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. BMJ 339: b4324-b4324 [Abstract] [Full Text]  
• Ong, H. T. (2009). Are Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Especially Useful for Cardiovascular Protection?. J Am Board Fam Med 22: 686-697 [Abstract] [Full Text]  
• Bertoni, A. G., Kitzman, D. W. (2009). Coronary Artery Calcium: A Clue to the Enigma of Tight Glycemic Control and Cardiovascular Disease?. Diabetes 58: 2448-2449 [Full Text]  
• Reaven, P. D., Moritz, T. E., Schwenke, D. C., Anderson, R. J., Criqui, M., Detrano, R., Emanuele, N., Kayshap, M., Marks, J., Mudaliar, S., Harsha Rao, R., Shah, J. H., Goldman, S., Reda, D. J., McCarren, M., Abraira, C., Duckworth, W., for the Veterans Affairs Diabetes Trial, (2009). Intensive Glucose-Lowering Therapy Reduces Cardiovascular Disease Events in Veterans Affairs Diabetes Trial Participants With Lower Calcified Coronary Atherosclerosis. Diabetes 58: 2642-2648 [Abstract] [Full Text]  
• Schlotterer, A., Kukudov, G., Bozorgmehr, F., Hutter, H., Du, X., Oikonomou, D., Ibrahim, Y., Pfisterer, F., Rabbani, N., Thornalley, P., Sayed, A., Fleming, T., Humpert, P., Schwenger, V., Zeier, M., Hamann, A., Stern, D., Brownlee, M., Bierhaus, A., Nawroth, P., Morcos, M. (2009). C. elegans as Model for the Study of High Glucose- Mediated Life Span Reduction. Diabetes 58: 2450-2456 [Abstract] [Full Text]  
• Raz, I. (2009). Introduction to the Second World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy): Dilemmas in clinical practice. Diabetes Care 32: S149-S150 [Full Text]  
• Monnier, L., Colette, C. (2009). Target for Glycemic Control: Concentrating on glucose. Diabetes Care 32: S199-S204 [Full Text]  
• Del Prato, S., Penno, G., Miccoli, R. (2009). Changing the Treatment Paradigm for Type 2 Diabetes. Diabetes Care 32: S217-S222 [Full Text]  
• Swinnen, S. G., Hoekstra, J. B., DeVries, J. H. (2009). Insulin Therapy for Type 2 Diabetes. Diabetes Care 32: S253-S259 [Full Text]  
• Bretzel, R. G., Eckhard, M., Landgraf, W., Owens, D. R., Linn, T. (2009). Initiating Insulin Therapy in Type 2 Diabetic Patients Failing on Oral Hypoglycemic Agents: Basal or prandial insulin? The APOLLO trial and beyond. Diabetes Care 32: S260-S265 [Full Text]  
• Nilsson, P. M. (2009). Hypertension and Diabetes: Should We Treat Early Surrogates?: What are the cons?. Diabetes Care 32: S290-S293 [Full Text]  
• Gallwitz, B. (2009). Implications of Postprandial Glucose and Weight Control in People With Type 2 Diabetes: Understanding and implementing the International Diabetes Federation guidelines. Diabetes Care 32: S322-S325 [Full Text]  
• Schnell, O., Otter, W., Standl, E. (2009). The Munich Myocardial Infarction Registry: Translating the European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD) guidelines on diabetes, pre-diabetes, and cardiovascular disease into clinical practice. Diabetes Care 32: S326-S330 [Full Text]  
• Kassem, S. A., Raz, I. (2009). Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity or Mortality? No. Diabetes Care 32: S337-S341 [Full Text]  
• Bianchi, C., Miccoli, R., Daniele, G., Penno, G., Del Prato, S. (2009). Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity/Mortality? Yes. Diabetes Care 32: S342-S348 [Full Text]  
• Hanefeld, M., Bornstein, S. R., Pistrosch, F. (2009). Shifting the Disease Management Paradigm From Glucose: What are the cons?. Diabetes Care 32: S353-S356 [Full Text]  
• Heller, S. R., on behalf of the ADVANCE Collaborative Group, (2009). A Summary of the ADVANCE Trial. Diabetes Care 32: S357-S361 [Full Text]  
• Wilper, A. P., Woolhandler, S., Lasser, K. E., McCormick, D., Bor, D. H., Himmelstein, D. U. (2009). Hypertension, Diabetes, And Elevated Cholesterol Among Insured And Uninsured U.S. Adults. Health Aff (Millwood) 28: w1151-w1159 [Abstract] [Full Text]  
• Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., Paul, S. K., the 4-T Study Group, (2009). Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes. NEJM 361: 1736-1747 [Abstract] [Full Text]  
• Psaty, B. M., Prentice, R. L. (2009). Variation in Event Rates in Trials of Patients With Type 2 Diabetes. JAMA 302: 1698-1700 [Full Text]  
• Hoehn, K. L., Salmon, A. B., Hohnen-Behrens, C., Turner, N., Hoy, A. J., Maghzal, G. J., Stocker, R., Van Remmen, H., Kraegen, E. W., Cooney, G. J., Richardson, A. R., James, D. E. (2009). Insulin resistance is a cellular antioxidant defense mechanism. Proc. Natl. Acad. Sci. USA 106: 17787-17792 [Abstract] [Full Text]  
• Mann, D. M., Woodward, M., Ye, F., Krousel-Wood, M., Muntner, P. (2009). Trends in Medication Use Among US Adults With Diabetes Mellitus: Glycemic Control at the Expense of Controlling Cardiovascular Risk Factors. Arch Intern Med 169: 1718-1720 [Full Text]  
• Bailey, C. J., Blonde, L., Del Prato, S., Leiter, L. A., Nesto, R., Global Partnership for Effective Diabetes Manageme, (2009). What are the practical implications for treating diabetes in light of recent evidence? Updated recommendations from the Global Partnership for Effective Diabetes Management. Diabetes and Vascular Disease Research 6: 283-287 [Abstract]  
• Fonseca, V. (2009). Adding metformin to insulin did not improve a composite of microvascular and macrovascular disease in type 2 diabetes. Evid. Based Med. 14: 139-139 [Full Text]  
• Mount, D. L, Feeney, P., Fabricatore, A. N, Coday, M., Bahnson, J., Byington, R., Phelan, S., Wilmoth, S., Knowler, W. C, Hramiak, I., Osei, K., Sweeney, M. E., Espeland, M. A (2009). Constructing common cohorts from trials with overlapping eligibility criteria: implications for comparing effect sizes between trials. Clin Trials 6: 416-429 [Abstract]  
• Belalcazar, L. M., Raghavan, V. A., Ballantyne, C. M. (2009). Statin-Induced Diabetes: Will It Change Clinical Practice?. Diabetes Care 32: 1941-1943 [Full Text]  
• Rosenstock, J., Reusch, J., Bush, M., Yang, F., Stewart, M., for the Albiglutide Study Group, (2009). Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 32: 1880-1886 [Abstract] [Full Text]  
• Mullan, R. J., Montori, V. M., Shah, N. D., Christianson, T. J. H., Bryant, S. C., Guyatt, G. H., Perestelo-Perez, L. I., Stroebel, R. J., Yawn, B. P., Yapuncich, V., Breslin, M. A., Pencille, L., Smith, S. A. (2009). The Diabetes Mellitus Medication Choice Decision Aid: A Randomized Trial. Arch Intern Med 169: 1560-1568 [Abstract] [Full Text]  
• Pradhan, A. D., Everett, B. M., Cook, N. R., Rifai, N., Ridker, P. M (2009). Effects of Initiating Insulin and Metformin on Glycemic Control and Inflammatory Biomarkers Among Patients With Type 2 Diabetes: The LANCET Randomized Trial. JAMA 302: 1186-1194 [Abstract] [Full Text]  
• Flegel, K. (2009). Controlling the complications of diabetes: It's about the sugar. CMAJ 181: 357-357 [Full Text]  
• Flegel, K. (2009). La maitrise des complications du diabete: une question de sucre. CMAJ 181: E106-E107 [Full Text]  
• Eggleston, K. N., Shah, N. D., Smith, S. A., Wagie, A. E., Williams, A. R., Grossman, J. H., Berndt, E. R., Long, K. H., Banerjee, R., Newhouse, J. P. (2009). The Net Value of Health Care for Patients With Type 2 Diabetes, 1997 to 2005. ANN INTERN MED 151: 386-393 [Abstract] [Full Text]  
• Cruickshank, J. K., Banerjee, M. (2009). Pregnancy glycemia to vascular risk: Nonglycemic diabetes?. CMAJ 181: 361-362 [Full Text]  
• Kelly, T. N., Bazzano, L. A., Fonseca, V. A., Thethi, T. K., Reynolds, K., He, J. (2009). Systematic Review: Glucose Control and Cardiovascular Disease in Type 2 Diabetes. ANN INTERN MED 151: 394-403 [Abstract] [Full Text]  
• Campbell, R. K., Miller, S. (2009). New Therapeutic Horizons: Mapping the Future of Glycemic Control With Incretin-based Therapy. The Diabetes Educator 35: 731-747 [Abstract] [Full Text]  
• Pignone, M. (2009). Decisions About Intensity of Glycemic Control Should Depend on Age and Functional Status. Clin. Diabetes 27: 147-148 [Full Text]  
• Riveline, J.-P., Teynie, J., Belmouaz, S., Franc, S., Dardari, D., Bauwens, M., Caudwell, V., Ragot, S., Bridoux, F., Charpentier, G., Marechaud, R., Hadjadj, S. (2009). Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system. Nephrol Dial Transplant 24: 2866-2871 [Abstract] [Full Text]  
• Manders, R. J., Pennings, B., Beckers, C. P., Aipassa, T. I, van Loon, L. J. (2009). Prevalence of daily hyperglycemia in obese type 2 diabetic men compared with that in lean and obese normoglycemic men: effect of consumption of a sucrose-containing beverage. Am. J. Clin. Nutr. 90: 511-518 [Abstract] [Full Text]  
• Van den Berghe, G., Schetz, M., Vlasselaers, D., Hermans, G., Wilmer, A., Bouillon, R., Mesotten, D. (2009). Intensive Insulin Therapy in Critically Ill Patients: NICE-SUGAR or Leuven Blood Glucose Target?. J. Clin. Endocrinol. Metab. 94: 3163-3170 [Abstract] [Full Text]  
• Webster, N. R., Galley, H. F. (2009). Does strict glucose control improve outcome?. Br J Anaesth 103: 331-334 [Full Text]  
• Riddle, M., Pencek, R., Charenkavanich, S., Lutz, K., Wilhelm, K., Porter, L. (2009). Randomized Comparison of Pramlintide or Mealtime Insulin Added to Basal Insulin Treatment for Patients With Type 2 Diabetes. Diabetes Care 32: 1577-1582 [Abstract] [Full Text]  
• Potenza, M. A., Gagliardi, S., De Benedictis, L., Zigrino, A., Tiravanti, E., Colantuono, G., Federici, A., Lorusso, L., Benagiano, V., Quon, M. J., Montagnani, M. (2009). Treatment of spontaneously hypertensive rats with rosiglitazone ameliorates cardiovascular pathophysiology via antioxidant mechanisms in the vasculature. Am. J. Physiol. Endocrinol. Metab. 297: E685-E694 [Abstract] [Full Text]  
• Dhar, G. C. (2009). Intensive glycemic control: Implications of the ACCORD, ADVANCE, and VADT trials for family physicians. cfp 55: 803-804 [Full Text]  
• Elley, C R., Kenealy, T. (2009). Intensive primary care treatment reduced cardiovascular risk factors in screen-detected type 2 diabetes. Evid. Based Med. 14: 108-108 [Full Text]  
• Cukierman-Yaffe, T., on behalf of the ACCORD-MIND Investigators, (2009). Relationship Between Baseline Glycemic Control and Cognitive Function in Individuals With Type 2 Diabetes and Other Cardiovascular Risk Factors: The Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) Trial: Response to Abbatecola and Paolisso. Diabetes Care 32: e103-e103 [Full Text]  
• Saydah, S., Tao, M., Imperatore, G., Gregg, E. (2009). GHb Level and Subsequent Mortality Among Adults in the U.S.. Diabetes Care 32: 1440-1446 [Abstract] [Full Text]  
• O'Keefe, J. H., Carter, M. D., Lavie, C. J. (2009). Primary and Secondary Prevention of Cardiovascular Diseases: A Practical Evidence-Based Approach. Mayo Clin Proc. 84: 741-757 [Abstract] [Full Text]  
• Simoons, M. L. (2009). Angiotensin-converting enzyme inhibition by perindopril in cardiovascular disease. Eur Heart J Suppl 11: E4-E8 [Abstract] [Full Text]  
• (2009). How Much Evidence Do We Need to Change Practices in Which We Firmly Believe?. JWatch General 2009: 1-1 [Full Text]  
• Aguilar, D., Bozkurt, B., Ramasubbu, K., Deswal, A. (2009). Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes.. J Am Coll Cardiol 54: 422-428 [Abstract] [Full Text]  
• Weinrauch, L. A., Lewis, E. F. (2009). Aiming for the best control of glycemia in patients with heart failure and type 2 diabetes the "sweet spot".. J Am Coll Cardiol 54: 429-431 [Full Text]  
• Preis, S. R., Pencina, M. J., Hwang, S.-J., D'Agostino, R. B. Sr, Savage, P. J., Levy, D., Fox, C. S. (2009). Trends in Cardiovascular Disease Risk Factors in Individuals With and Without Diabetes Mellitus in the Framingham Heart Study. Circulation 120: 212-220 [Abstract] [Full Text]  
• Narendran, P. (2009). Cardiovascular benefit of intensive glucose control: approaching closure. British Journal of Diabetes & Vascular Disease 9: 175-176 [Abstract]  
• Wilding, J. (2009). Results of the LEAD-2 study in relation to NICE and ADA/EASD guidelines for the treatment of type 2 diabetes in the UK. British Journal of Diabetes & Vascular Disease 9: 177-185 [Abstract]  
• Hemmingsen, B., Lund, S. S, Wetterslev, J., Vaag, A. (2009). Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes. Eur J Endocrinol 161: 1-9 [Abstract] [Full Text]  
• Lund, S. S., Vaag, A. A. (2009). Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association: Response to Skyler et al.. Diabetes Care 32: e90-e91 [Full Text]  
• van Biesen, W., Van Laecke, S., Vanholder, R. (2009). Treatment of type 2 diabetes in chronic kidney disease: meekly follow the herd or call to arms?. Nephrol Dial Transplant 24: 2286-2287 [Full Text]  
• Morath, C., Zeier, M. (2009). Transplantation in type 1 diabetes. Nephrol Dial Transplant 24: 2026-2029 [Full Text]  
• Fonseca, V., Inzucchi, S. E., Ferrannini, E. (2009). Redefining the Diagnosis of Diabetes Using Glycated Hemoglobin. Diabetes Care 32: 1344-1345 [Full Text]  
• Shea, S., Weinstock, R. S., Teresi, J. A., Palmas, W., Starren, J., Cimino, J. J., Lai, A. M., Field, L., Morin, P. C., Goland, R., Izquierdo, R. E., Ebner, S., Silver, S., Petkova, E., Kong, J., Eimicke, J. P., IDEATel Consortium, (2009). A Randomized Trial Comparing Telemedicine Case Management with Usual Care in Older, Ethnically Diverse, Medically Underserved Patients with Diabetes Mellitus: 5 Year Results of the IDEATel Study. J. Am. Med. Inform. Assoc. 16: 446-456 [Abstract] [Full Text]  
• Cefalu, W. T. (2009). Mortality and Glycemic Targets in the Intensive Care Unit: Another Paradigm Shift?. Diabetes 58: 1469-1470 [Full Text]  
• Despres, J.-P. (2009). Targeting abdominal obesity and the metabolic syndrome to manage cardiovascular disease risk. Heart 95: 1118-1124 [Full Text]  
• Kazempour-Ardebili, S., Lecamwasam, V. L., Dassanyake, T., Frankel, A. H., Tam, F. W.K., Dornhorst, A., Frost, G., Turner, J. J.O. (2009). Assessing Glycemic Control in Maintenance Hemodialysis Patients With Type 2 Diabetes. Diabetes Care 32: 1137-1142 [Abstract] [Full Text]  
• Nauck, M. A., Ratner, R. E., Kapitza, C., Berria, R., Boldrin, M., Balena, R. (2009). Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: A double-blind placebo-controlled study. Diabetes Care 32: 1237-1243 [Abstract] [Full Text]  
• Marwick, T. H., Hordern, M. D., Miller, T., Chyun, D. A., Bertoni, A. G., Blumenthal, R. S., Philippides, G., Rocchini, A., on behalf of the American Heart Association Exerci, (2009). Exercise Training for Type 2 Diabetes Mellitus: Impact on Cardiovascular Risk: A Scientific Statement From the American Heart Association. Circulation 119: 3244-3262 [Full Text]  
• Pogach, L. M. (2009). Pharmacoepidemiology of insulin initiation in diabetes care. CMAJ 180: 1287-1288 [Full Text]  
• Perez, N., Moisan, J., Sirois, C., Poirier, P., Gregoire, J.-P. (2009). Initiation of insulin therapy in elderly patients taking oral antidiabetes drugs. CMAJ 180: 1310-1316 [Abstract] [Full Text]  
• Allen, L. A., Hernandez, A. F., O'Connor, C. M., Felker, G. M. (2009). End points for clinical trials in acute heart failure syndromes.. J Am Coll Cardiol 53: 2248-2258 [Abstract] [Full Text]  
• The BARI 2D Study Group, (2009). A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease. NEJM 360: 2503-2515 [Abstract] [Full Text]  
• Comi, R. J. (2009). Glucose Control in the Intensive Care Unit: A Roller Coaster Ride or a Swinging Pendulum?. ANN INTERN MED 150: 809-811 [Abstract] [Full Text]  
• Montori, V. M., Fernandez-Balsells, M. (2009). Glycemic Control in Type 2 Diabetes: Time for an Evidence-Based About-Face?. ANN INTERN MED 150: 803-808 [Abstract] [Full Text]  
• Clement, M., Bhattacharyya, O., Conway, J. R. (2009). Is tight glycemic control in type 2 diabetes really worthwhile?: YES. cfp 55: 580-582 [Full Text]  
• Wilson, G., Perry, T. (2009). Is tight glycemic control in type 2 diabetes really worthwhile?: NO. cfp 55: 581-583 [Full Text]  
• Clement, M., Bhattacharyya, O., Conway, J. R. (2009). Vaut-il vraiment la peine d'exercer un strict controle glycemique pour le diabete de type 2?: OUI. cfp 55: 584-588 [Full Text]  
• Wilson, G., Perry, T. (2009). Vaut-il vraiment la peine d'exercer un strict controle glycemique pour le diabete de type 2?: NON. cfp 55: 585-588 [Full Text]  
• Nahas, R., Moher, M. (2009). Complementary and alternative medicine for the treatment of type 2 diabetes. cfp 55: 591-596 [Abstract] [Full Text]  
• Haynes, R B., Haynes, G. A (2009). What does it take to put an ugly fact through the heart of a beautiful hypothesis?. Evid. Based Med. 14: 68-69 [Full Text]  
• Booth, G. L (2009). Intensive and standard glucose control did not differ for CV events or death in poorly controlled type 2 diabetes. Evid. Based Med. 14: 73-73 [Full Text]  
• Diener, H.-C., Weimar, C. (2009). Update of secondary stroke prevention. Nephrol Dial Transplant 24: 1718-1724 [Full Text]  
• McEwen, L. N., Bilik, D., Johnson, S. L., Halter, J. B., Karter, A. J., Mangione, C. M., Subramanian, U., Waitzfelder, B., Crosson, J. C., Herman, W. H. (2009). Predictors and Impact of Intensification of Antihyperglycemic Therapy in Type 2 Diabetes: Translating Research into Action for Diabetes (TRIAD). Diabetes Care 32: 971-976 [Abstract] [Full Text]  
• Catalano, P. M., Presley, L., Minium, J., Hauguel-de Mouzon, S. (2009). Fetuses of Obese Mothers Develop Insulin Resistance in Utero. Diabetes Care 32: 1076-1080 [Abstract] [Full Text]  
• Buse, J. B., Wolffenbuttel, B. H.R., Herman, W. H., Shemonsky, N. K., Jiang, H. H., Fahrbach, J. L., Scism-Bacon, J. L., Martin, S. A. (2009). DURAbility of Basal Versus Lispro Mix 75/25 Insulin Efficacy (DURABLE) Trial 24-Week Results: Safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care 32: 1007-1013 [Abstract] [Full Text]  
• Moen, M. F., Zhan, M., Hsu, V. D., Walker, L. D., Einhorn, L. M., Seliger, S. L., Fink, J. C. (2009). Frequency of Hypoglycemia and Its Significance in Chronic Kidney Disease. CJASN 4: 1121-1127 [Abstract] [Full Text]  
• Goode, K M, John, J, Rigby, A S, Kilpatrick, E S, Atkin, S L, Bragadeesh, T, Clark, A L, Cleland, J G F (2009). Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus. Heart 95: 917-923 [Abstract] [Full Text]  
• Hall, G. M., Nicholson, G. (2009). Current Therapeutic Drugs for Type 2 Diabetes, Still Useful After 50 Years?. Anesth. Analg. 108: 1727-1730 [Full Text]  
• Griffin, S., Graffy, J. (2009). New QOF glycaemia targets are achievable and evidence based. BMJ 338: b1915-b1915 [Full Text]  
• Banarer, S., Luan, F. L., Duckworth, W. C., Moritz, T., Abraira, C. (2009). Glucose Control and Vascular Complications in Type 2 Diabetes. NEJM 360: 2031-2032 [Full Text]  
• Matfin, G. (2009). Diabetes P4P: a view from near and far. British Journal of Diabetes & Vascular Disease 9: 96-97  
• Gellad, W. F., Detsky, A. S., Choudhry, N. K. (2009). Implications of recent clinical trials on pay-for-performance. Am J Health Syst Pharm 66: 864-867 [Full Text]  
• Verhaert, D., Thomas, J. D. (2009). Dysglycemia and acute myocardial infarction the role of echocardiography.. J Am Coll Cardiol Img 2: 600-603 [Full Text]  
• Parving, H.-H., Brenner, B. M., McMurray, John. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Ghadanfar, M., Weissbach, N., Xiang, Z., Armbrecht, J., Pfeffer, M. A. (2009). Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 24: 1663-1671 [Abstract] [Full Text]  
• Brasacchio, D., Okabe, J., Tikellis, C., Balcerczyk, A., George, P., Baker, E. K., Calkin, A. C., Brownlee, M., Cooper, M. E., El-Osta, A. (2009). Hyperglycemia Induces a Dynamic Cooperativity of Histone Methylase and Demethylase Enzymes Associated With Gene-Activating Epigenetic Marks That Coexist on the Lysine Tail. Diabetes 58: 1229-1236 [Abstract] [Full Text]  
• Doucette, W. R, Witry, M. J, Farris, K. B, McDonough, R. P (2009). Community Pharmacist-Provided Extended Diabetes Care. The Annals of Pharmacotherapy 43: 882-889 [Abstract] [Full Text]  
• Brice, R. (2009). A taxi driver with type 2 diabetes. BMJ 338: b1369-b1369 [Full Text]  
• Cheng, A. Y.Y., Leiter, L. A. (2009). Cardiovascular risk and glycemic control. CMAJ 180: 907-908 [Full Text]  
• Ko, G. T.C., So, W.-Y., Tong, P. C., Chan, W.-B., Yang, X., Ma, R. C., Kong, A. P., Ozaki, R., Yeung, C.-Y., Chow, C.-C., Chan, J. C. (2009). Effect of interactions between C peptide levels and insulin treatment on clinical outcomes among patients with type 2 diabetes mellitus. CMAJ 180: 919-926 [Abstract] [Full Text]